News Releases

Tobira Therapeutics to Participate in Two Conferences in February

SOUTH SAN FRANCISCO, Calif., Feb. 1, 2016 /PRNewswire/ -- Tobira Therapeutics, Inc. (NASDAQ: TBRA) today announced that company management will present an overview of the company at the following conferences in February.

  • 18th Annual BIO CEO & Investor Conference
    • Presentation date: Tuesday, February 9, 2016
    • Presentation time: 3:30 p.m. ET
  • Leerink Partners 5th Annual Global Healthcare Conference
    • Presentation date: Wednesday, February 10, 2016
    • Presentation time: 3:55 p.m. ET

A live webcast and 30-day archive of these presentations will be available at

About Tobira Therapeutics
Tobira is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and HIV. The company's lead product candidate, cenicriviroc (CVC), is a first-in-class immunomodulator and dual inhibitor of CCR2 and CCR5 being evaluated for the treatment of non-alcoholic steatohepatitis (NASH). Learn more about Tobira at

Tobira® is a registered trademark owned by Tobira Therapeutics, Inc.

©2016 Tobira Therapeutics, Inc. All Rights Reserved.

Tobira Investor & Media Contact:
Ian Clements, Ph.D.
+1 (650) 351-5013

Canale Communications Media Contact:
Pam Lord
+1 (619) 849-6003


SOURCE Tobira Therapeutics, Inc.